# Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

> **NCT05144347** · PHASE1 · TERMINATED · sponsor: **Exelixis** · enrollment: 2 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma (NHL)
- Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)
- Mantle Cell Lymphoma (MCL)
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)

## Interventions

- **DRUG:** XL114

## Key facts

- **NCT ID:** NCT05144347
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-12
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Due to Sponsor reasons.
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05144347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05144347, "Study of XL114 in Subjects With Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05144347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*